Polyamine Biomarker Composition for Nanoparticle Neurotoxicity Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers and diagnostic tools for assessing the neurotoxicity of nanoparticles, particularly in relation to their impact on neuronal tissues, as research on nano-neurotoxicity is still in its early stages and relies heavily on conventional chemical toxicity laws.
Innovation Solution
A biomarker composition and microarray chip that detect polyamine metabolites and genes such as putrescine, N1-acetylspermidine, N8-acetylspermidine, N1-acetylspermine, spermine, ODC1, SAT1, PAOX, and SRM1 to evaluate neurotoxicity by analyzing tissue or cell samples exposed to nanoparticles, comparing expression levels to control samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional chemical toxicity laws are used to assess nanoparticle toxicity, then general toxicity evaluation can be performed, but specific neurotoxicity assessment is insufficient
Solution Approach 1:
The patent segments the general toxicity assessment into specific neurotoxicity evaluation by identifying and measuring polyamine metabolites (putrescine, spermidine, spermine) and related gene expressions specifically in neuronal tissues, thereby achieving precise neurotoxicity assessment while maintaining the framework of conventional toxicity evaluation
Solution Approach 2:
The patent applies local quality by focusing on specific biochemical markers (polyamine metabolites and their synthesizing genes) that are particularly relevant to neuronal health and function, rather than using general toxicity markers, thus enabling specialized neurotoxicity detection
2Reliability
If research on nano-neurotoxicity is conducted using early-stage methods, then some toxicity indicators can be identified, but reliable biomarkers and diagnostic tools are lacking
Solution Approach 1:
The patent performs preliminary identification and validation of polyamine metabolites and their associated genes as reliable neurotoxicity biomarkers through systematic analysis, establishing a foundation for future diagnostic tool development and standardization
Solution Approach 2:
The patent introduces polyamine metabolites and their synthesizing genes as intermediary biomarkers that mediate between nanoparticle exposure and neuronal damage, providing measurable indicators that bridge the gap between initial exposure and observable neurotoxicity effects
3Productivity
If the size of nanoparticles is reduced to increase surface area ratio, then industrial and medical applications are enhanced, but toxicity to biological tissues increases
Solution Approach 1:
The patent changes the assessment parameters from general toxicity markers to specific polyamine metabolite levels and gene expressions, enabling differentiation between functional benefits and toxic effects of reduced nanoparticle size, thus allowing optimized nanoparticle design
4Speed
If nanoparticles penetrate deep into tissues such as alveoli and brain, then delivery efficiency is improved, but accumulation and disease causation risk increase
Solution Approach 1:
The patent establishes a feedback mechanism by measuring polyamine metabolite levels and gene expressions in tissues after nanoparticle exposure, providing information about accumulation and toxicity risk that can guide adjustments in nanoparticle dosing, size, or composition to minimize harmful effects
Data Source
AI summary
A method of assessing neurotoxicity of nanoparticles, includes: preparing a tissue or cell sample of mammal exposed to the nanoparticles; analyzing at least one polyamine metabolite selected from the group consisting of putrescine, N1-acetylspermidine, N8-acetylspermidine, N1-acetylspermine and spermine in the sample; and comparing expression degree of the polyamine metabolite with that of a control.